A PROSPECTIVE DOUBLE BLIND COMPARATIVE STUDY OF MEDICATIONS PRESCRIBED FOR THE TREATMENT OF PATIENTS WITH KNEE OSTEOARTHRITIS

Mogoi Okenye R; Dr. J.Nandhakumar

Volume : X, Issue : VII, July - 2020

A PROSPECTIVE DOUBLE BLIND COMPARATIVE STUDY OF MEDICATIONS PRESCRIBED FOR THE TREATMENT OF PATIENTS WITH KNEE OSTEOARTHRITIS

Mogoi Okenye R, Dr. J. Nandhakumar

Abstract :

Introduction: Knee Osteoarthritis (KOA), is a degenerative joint disease, which is extremely common in persons over 35 yrs of age and is one of the most prevalent diseases of elderly people. KOA eaks down the cartilage in our joints which when affected our bones rub together causing pain, swelling and loss of motion of joint. There are ‘n’ numbers of combinations are being used for therapy of KOA. In our study, we have chosen GlcN1 (glucosamine sulfate with potassium chloride), GlcN2 (glucosamine sulfate plus chondroitin sulfate) along with ChoN3 (chondroitin sulfate alone)] in the treatment of knee osteoarthritis. Methods: A total number of 135 patients with KOA were divided into three groups, first group received GlcN1 500 mg of glucosamine sulfate with potassium chloride one capsule thrice daily for 12 weeks. Second group received GlcN2, containing glucosamine sulfate 500 mg plus chondroitin sulfate 400 mg, 2 capsules thrice daily for 12 weeks. Third group received ChoN3, chondroitin sulfate 400 mg, methyl sulfonyl methane 250 mg and manganese 20 mg, one tablet thrice daily for 12 weeks. In this study, we observed correlation of measurement of urinary pyridinium cross links such as pyridinoline (Pyr) and deoxypyridinoline (Dpyr). Results: In this study, WOMAC scores pertaining to daily activities were compared with different time intervals as well as between treatment groups. In GlcN2 and ChoN3 group the difference in WOMAC daily activity scores was significantly (P<0.001) decreasing at the end of 4,8,12 and 16 weeks of therapy, compared to base line. In over all the WOMAC score of pain, stiffness and difficulty in performing daily activities was retained significantly (P<0.001) at the end of 16 weeks even after stoppage of drug therapy. The level of Pyr excretion in urine was significantly (P<0.001) diminishing in GlcN2 and ChoN3 group when compared to GlcN1 group at different time intervals (after 8, 12 and 16 weeks) even after stoppage of drug treatment. Conclusion: The present study concludes that GlcN2 and ChoN3 have superior efficacy and safety in view of relieve pain, improving functional ability and joint mobility so as to enhance the quality of life for KOA patients rather than GlcN1.